ResMed Inc. (RMB) has shown significant positive movements over the past year. Not only has the stock price climbed 25.6%, it has also crushed earnings expectations with a 52% profit jump and record margins, resulting in an invitation to a very exclusive stock group. This trend has been attributed to ResMed's strong growth, despite pessimistic forecasts from Stifel Nicolaus. Six analysts have discussed the stock, implying extensive coverage. CEO Peter Farrell and CFO Brett Sandercock have sold shares, suggesting potential insider sentiment. However, the company remains a strong choice for growth investors and shows impressive earnings-per-share (EPS) growth. While the stock price has been affected by variations in organic sales growth, ResMed's revenue has risen 10% in Q2 and the firm showcases robust financial prospects. Investors who took a five-year stake in ResMed have seen a 56% gain. However, some weakness has been identified in ResMed's institutional ownership despite it being a top growth stock for the long term. There is an ongoing investigation into potential securities fraud.
Nevertheless, the company's Q2 results highlight strong revenue growth. Overall, ResMed presents a compelling investment opportunity with considerable upside potential based on its impressive financial performance and market position.
Resmed RMD News Analytics from Fri, 26 Apr 2024 07:00:00 GMT to Fri, 07 Mar 2025 17:16:43 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -6
